



# SVEIRS Mathematical Model on Stability Analysis of HIV-1 Coronavirus CO- Infection

Cherono Pela <sup>a\*</sup>, Kirui Wesley <sup>b</sup> and Adicka Daniel <sup>a</sup>

<sup>a</sup> Department of Mathematics and Computer Science, University of Kabianga, Kericho, Kenya.

<sup>b</sup> Department of Mathematics and Actuarial Science, South Eastern Kenya University, Kitui, Kenya.

## Authors' contributions

*This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.*

## Article Information

DOI: 10.9734/JAMCS/2024/v39i51895

## Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/116815>

**Received: 01/03/2024**

**Accepted: 01/05/2024**

**Published: 04/05/2024**

**Original Research Article**

## Abstract

Mathematical modeling has enabled epidemiologist to understand best the dynamics of infectious diseases, their impact and future predictions on their transmission and existence. Deterministic Susceptible–Vaccinated–Exposed–Infectious–Recovered (SVEIR) model on HIV-1 Coronavirus co-infection was formulated based on piecewise linear dynamical systems with constant delay. Delay here accounts for the time lapse between exposure and when the symptoms of the disease appear. Basic reproduction number  $R_0$  is the threshold parameter on which the growth or reduction of the disease is based and calculated using Next Generation Matrix approach. Disease Free Equilibrium is attained when reproduction number is less or equals to one. The Disease Free Equilibrium is globally asymptotically stable whenever the reproductive number is less or equal to one and unstable otherwise and it is showed using Lyapunov function. Numerical simulation is performed using Matrix Laboratory (MatLab) dde23 solver to authenticate the analytic results. Graphical representation is then done so as to highlight on future disease dynamics and interventions. Time-delay, vaccination and chemotherapy plays a major role in stabilizing disease free equilibrium.

\*Corresponding author: Email: pelacherono@gmail.com;

*Keywords: Coronavirus; basic reproduction number; global stability; lyapunov's function.*

## 1 Introduction

There is a widespread concern worldwide over the emergence of new infectious disease that have wrecked havoc on human population. Human immunodeficiency virus 1 (HIV-1) and coronavirus disease are infectious diseases that have been of great concern to both scientists and medical practitioners in the recent past. The main purpose of this study was to investigate the impacts of protection with quarantine, CoVid-19 vaccination, HIV-1 and CoVid-19 chemotherapy, controlling and prevention strategies on transmission dynamics of HIV-1 and AIDs and CoVid-19 co-infection. A mathematical modeling approach was thus used in which a deterministic Susceptible-Vaccinated-Exposed-Infected-Removed (SVEIR) HIV-1 Covid-19 co-infection model was formulated. The model considers the time lag that occurs between exposure of the Coronavirus disease and when the disease appears and its effects. Delay differential equations (DDEs) with constant delay were formulated. [1,2,3,4,5,6,7].

According to [8,9,10,11,12] HIV and COVID-19 co-infection model with ABC-fractional operator approach was formulated to investigate an epidemic prediction of combined HIV-COVID-19 co-infection. Numerical simulations carried out established that the disease would stabilize at a later stage when enough protection strategies are taken. A mathematical model on HIV and COVID-19 co-infection with optimal control strategies were formulated and analyzed by [13,14,15,16,17]. The analysis suggested that COVID-19 only prevention strategy is the most effective strategy and it averted about 10,500 new co-infection cases. Further, [18,19,20,21,22] studied analysis of COVID-19 and comorbidity specifically diabetes mellitus co-infection model with optimal control. The model showed backward bifurcation caused by parameter accounting for susceptibility for Covid-19 and rate of reinfection. According to [23,24,25,26] they constructed and examined HIV/AIDS and Pneumonia co-infection model with control measures such as pneumonia vaccination and treatment of pneumonia and HIV/AIDS infections. Numerical simulations on the model showed that pneumonia treatment and vaccination played a major role in reducing pneumonia and co-epidemic disease growth while at the same time decreasing the growth rate of HIV infection to the AIDS stage. A mathematical model for cholera and COVID-19 co-infection which describes the transmission dynamics of COVID-19 and cholera in Yemen was studied by [27,25,28,29]. The results showed that preventive measures such as number of chlorine water tablets, lockdown, social distancing and number of tests played a key role in reducing spread of the disease. COVID-19 and tuberculosis co-dynamics model with optimal control strategies carried out by [30,13,31,22] suggested that COVID-19 prevention, treatment and control of co-infection yields a better outcome in terms of the number of COVID-19 cases prevented at a lower percentage of the total cost of this strategy. Ordinary differential equations constructed by [32,33,34,35] modeled bifurcation and optimal control analysis of HIV/AIDS and COVID-19 co-infection model with numerical simulation. The main purpose of this paper was to investigate the impacts of COVID-19 protection with quarantine, COVID-19 treatment, HIV protection and HIV treatment prevention and controlling strategies on the transmission dynamics of HIV/AIDS and COVID-19 co-infection in the community with mathematical approach. The  $R_0$  value of the SQEIRP model is 3.78, meaning that one patient can lead to approximately three additional infections.

In this study, a deterministic SVEIR HIV-1 Coronavirus co-infection model was formulated to take into account the time lag that occurs between the exposure of a Coronavirus disease and its effects. Delay differential equations DDEs with constant delay were formulated. Local and global stability of disease free equilibrium, bifurcation analysis and type of bifurcation were taken into account.

## 2 Methodology

In the study, the total population were partitioned into twelve compartments basing on their infection status: susceptible class to both HIV-1 and Coronavirus disease ( $S$ ), individuals vaccinated against Coronavirus disease ( $V$ ), individuals not vaccinated against Coronavirus disease ( $V_n$ ), Exposed class ( $E$ ), Exposed class with HIV-1 ( $E_h$ ), Exposed class with AIDs ( $E_A$ ), symptomatic infected individuals with AIDs ( $I_{SA}$ ), symptomatic infected class with HIV-1 ( $I_{sh}$ ), asymptomatic infected class with HIV-1 ( $I_{ah}$ ), Quarantined class with HIV-1 ( $Q_h$ ), Hospitalized class ( $H$ ) and Removed class ( $R$ ). Other parameters considered are:

Recruitment rate ( $\phi_2$ ), rate of progression from S to V ( $\beta_3$ ), Rate of progression from S to  $V_n$  ( $\beta_4$ ), rate of progression from V to E ( $\alpha_3$ ), Rate of progression from  $V_n$  to E ( $\alpha_4$ ), Rate of progression from V to R ( $\alpha_5$ ), Rate of progression from E to  $E_h$  ( $\omega_3$ ), Rate of progression from E to  $E_A$  ( $\omega_4$ ), Rate of progression from  $E_A$  to  $I_{SA}$  ( $\omega_5$ ), Rate of progression from  $E_h$  to  $I_{sh}$  ( $\omega_6$ ), Rate of progression from  $E_h$  to  $I_{ah}$  ( $\omega_7$ ), Rate of progression from H to R ( $\gamma_2$ ), Rate of progression from  $I_{sh}$  to  $Q_h$  ( $\gamma_3$ ), Rate of progression from  $I_{SA}$  to H ( $\gamma_4$ ), Rate of progression from  $I_{ah}$  to H ( $\gamma_5$ ), Rate of progression from  $Q_h$  to R ( $\delta_4$ ), Rate of progression from  $Q_h$  to H ( $\delta_5$ ), Natural death rate ( $\mu$ ) and time delay ( $\tau$ ).




Fig. 1. SVEIR co-infection model

$$\begin{aligned}
 \frac{ds}{dt} &= \phi_2 - \mu_5 S - \beta_2 S - \beta_3 S \\
 \frac{dV}{dt} &= \beta_2 S - \mu_6 V - \alpha_2 V_\tau - \alpha_4 V_\tau \\
 \frac{dV_n}{dt} &= \beta_3 S - \mu_7 V_n - \alpha_3 V_{n\tau} \\
 \frac{dE}{dt} &= \alpha_2 V_\tau + \alpha_3 V_{n\tau} - \mu_8 E - \omega_2 E_\tau - \omega_3 E_\tau \\
 \frac{dE_A}{dt} &= \omega_3 E_\tau - \mu_9 E_A - \omega_4 E_{A\tau} \\
 \frac{dE_h}{dt} &= \omega_2 E_\tau - \mu_{10} E_h - \omega_5 E_{h\tau} - \omega_6 E_{h\tau} \\
 \frac{dI_{sh}}{dt} &= \omega_5 E_{h\tau} - \mu_{11} I_{sh} - \gamma_1 I_{sh\tau} \\
 \frac{dI_{ah}}{dt} &= \omega_6 E_{h\tau} - \mu_{12} I_{ah} - \gamma_2 I_{ah\tau} \\
 \frac{dI_{SA}}{dt} &= \omega_4 E_{A\tau} - \mu_{13} I_{SA} - \gamma_3 I_{SA\tau} \\
 \frac{dQ_h}{dt} &= \gamma_1 I_{sh\tau} - \delta_1 Q_{h\tau} - \delta_2 Q_{h\tau} - \mu_{14} Q_h \\
 \frac{dH}{dt} &= \gamma_2 I_{SA\tau} + \gamma_3 I_{ah\tau} + \delta_2 Q_{h\tau} - \mu_{15} H - \Gamma_1 H_\tau \\
 \frac{dR}{dt} &= \delta_1 Q_{h\tau} + \Gamma_1 H_\tau + \alpha_4 V_\tau - \mu_{16} R
 \end{aligned}$$

System 1 (\*)

## 2.1 Model preliminary analysis

### 2.1.1 Properties of solutions of the model

Positivity and boundedness of the model is shown before doing result analysis for biological reasons. Transformation of population of cell is well elaborated such that cell numbers remain positive and bounded and existence of solutions are underscored by these properties.

Let's define a positive quadrant space  $C = C^1([-\tau, 0]; \mathbb{R}^{12})$  equipped with the norm  $\|\Phi\| = \sup_{t \in [-\tau, 0]} \Phi(t)$  as a Banach space of continuous functions mapping the  $[-\tau, 0]$  into  $\mathbb{R}^{12}$  with the topology of uniform convergence. Let the positive initial conditions of system 1 (\*) at a time  $t = t_0$  be

$$\begin{aligned} S(t_0) = S_0 \geq 0, V(t_0) = V_0 \geq 0, (V_n(t_0) = V_{n_0} \geq 0, E(t_0) = E_0 \geq 0, E_A(t_0) = E_{A_0} \geq 0, E_h(t_0) = E_{h_0} \geq 0, \\ I_{sh}(t_0) = I_{sh_0} \geq 0, I_{ah}(t_0) = I_{ah_0} \geq 0, I_{sA}(t_0) = I_{sA_0} \geq 0, Q_h(t_0) = Q_{h_0} \geq 0, H_h(t_0) = H_{h_0} \geq 0, \\ R(t_0) = R_0 \geq 0, t_0 \in [-\tau, 0] \end{aligned} \tag{1}$$

In this case, we define a positive quadrant space of solutions as

$$\mathbb{R}_{+0} = \{(S, V, V_n, E, E_A, E_h, I_{sh}, I_{ah}, I_{sA}, Q_h, H_h, R) | S \geq 0, V \geq 0, V_n \geq 0, E \geq 0, E_A \geq 0, E_h \geq 0, I_{sh} \geq 0, I_{ah} \geq 0, I_{sA} \geq 0, Q_h \geq 0, H_h \geq 0, R \geq 0\} \tag{2}$$

$$\mathbb{R}_+ = \{(S, V, V_n, E, E_A, E_h, I_{sh}, I_{ah}, I_{sA}, Q_h, H_h, R) | S > 0, V > 0, V_n > 0, E > 0, E_A > 0, E_h > 0, I_{sh} > 0, I_{ah} > 0, I_{sA} > 0, Q_h > 0, H_h > 0, R > 0\} \tag{3}$$

By fundamental theory of differential equations it can be shown that there exists a unique solution  $(S(t), V(t), V_n(t), E(t), E_A(t), E_h(t), I_{sh}(t), I_{ah}(t), I_{sA}(t), Q_h(t), H_h(t), R(t))$  of the system 1(\*) with initial data in  $\mathbb{R}_+$  as follows:

From system 1 (\*), by integrating we have

$$s(t) = S(0)e^{\int_0^t (\mu_5 + \beta_2 + \beta_3)d\eta} + \int_0^t (\phi_1 + (\mu_5 + \beta_2 + \beta_3))S(\xi)e^{\int_0^t (\mu_5 + \beta_2 + \beta_3)d\eta} d\xi \tag{4}$$

From (4) it's clearly seen that  $S(t) > 0$  hence positive.

Similarly, it can be shown that

$$(V(t) > 0, V_n(t) > 0, E(t) > 0, E_A(t) > 0, E_h(t) > 0, I_{sh} > 0, I_{ah} > 0, I_{sA} > 0, Q_h > 0, H_h > 0, R > 0) \tag{5}$$

Using (4) positivity immediately follows from the above integral forms.

For boundedness we define;

$$N(t) = S(t) + V(t) + V_n(t) + E(t) + E_A(t) + E_h(t) + I_{sh}(t) + I_{ah}(t) + I_{sA}(t) + Q_h(t) + H_h(t) + R(t) \tag{6}$$

$$\frac{dN(t)}{dt} = \frac{d(S(t)+V(t)+V_n(t)+E(t)+E_A(t)+E_h(t)+I_{sh}(t)+I_{ah}(t)+I_{sA}(t)+Q_h(t)+H_h(t)+R(t))}{dt} \tag{7}$$

Thus,

$$\frac{dN(t)}{dt} \leq \phi_2 - \sum \mu. \text{ Where } \sum \mu = \mu_1 + \mu_2 + \dots + \mu_{12}. \tag{8}$$

This implies that  $N(t)$  is bounded and so

$$(S(t), V(t), V_n(t), E(t), E_A(t), E_h(t), I_{sh}(t), I_{ah}(t), I_{sA}(t), Q_h(t), H_h(t), R(t)).$$

### 2.3 Computation of basic reproductive number $R_0$

Fig. 1. SVEIR co-infection model.

In system 1 there are seven infection classes:  $E, E_A, E_h, I_{sh}, I_{ah}, I_{sA}, Q_h$ . Therefore, at disease free equilibrium (DFE) the matrix of new infection is given by matrices  $F$  and  $V$ .

$$\mathcal{F}_i = \begin{bmatrix} (\omega_2 + \omega_3)E_\tau \\ \omega_4 E_{A\tau} \\ (\omega_5 + \omega_6)E_{h\tau} \\ \gamma_1 I_{sh\tau} \\ \gamma_2 I_{ah\tau} \\ \gamma_3 I_{sA\tau} \\ \delta_2 Q_{h\tau} \end{bmatrix} \quad \mathcal{V}_i = \begin{bmatrix} -\mu_8 E \\ -\mu_9 E_A \\ -\mu_{10} E_h \\ -\mu_{11} I_{sh} \\ -\mu_{12} I_{ah} \\ -\mu_{13} I_{sA} \\ \delta_2 Q_{h\tau} - \mu_{14} Q_h \end{bmatrix}$$

Differentiating partially with respect to state variables we have:

$$F = \begin{bmatrix} (\omega_2 + \omega_3)e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & \omega_4 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & (\omega_5 + \omega_6)e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & \gamma_1 e^{-\lambda\tau} & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & \gamma_2 e^{-\lambda\tau} & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & \gamma_3 e^{-\lambda\tau} & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & \delta_2 e^{-\lambda\tau} \end{bmatrix}$$

$$V = \begin{bmatrix} -\mu_8 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -\mu_9 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -\mu_{10} & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -\mu_{11} & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\mu_{12} & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & -\mu_{13} & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & \delta_1 e^{-\lambda\tau} - \mu_{14} \end{bmatrix}$$

$$V^{-1} = \begin{bmatrix} -\frac{1}{\mu_8} & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -\frac{1}{\mu_9} & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -\frac{1}{\mu_{10}} & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -\frac{1}{\mu_{11}} & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\frac{1}{\mu_{12}} & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & -\frac{1}{\mu_{13}} & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & -\frac{1}{\delta_2 e^{-\lambda\tau} - \mu_{14}} \end{bmatrix}$$

$$FV^{-1} = \begin{bmatrix} -\frac{(\omega_2 + \omega_3)e^{-\lambda\tau}}{\mu_8} & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -\frac{\omega_4 e^{-\lambda\tau}}{\mu_9} & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -\frac{(\omega_5 + \omega_6)e^{-\lambda\tau}}{\mu_{10}} & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -\frac{\gamma_1 e^{-\lambda\tau}}{\mu_{11}} & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\frac{\gamma_2 e^{-\lambda\tau}}{\mu_{12}} & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & -\frac{\gamma_3 e^{-\lambda\tau}}{\mu_{13}} & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & -\frac{\delta_1 e^{-\lambda\tau}}{\delta_2 e^{-\lambda\tau} - \mu_{14}} \end{bmatrix}$$

To find the eigenvalues we have;

$$\begin{bmatrix} -\frac{(\omega_2 + \omega_3)e^{-\lambda\tau}}{\mu_8} - \lambda & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -\frac{\omega_4 e^{-\lambda\tau}}{\mu_9} - \lambda & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -\frac{(\omega_5 + \omega_6)e^{-\lambda\tau}}{\mu_{10}} - \lambda & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -\frac{\gamma_1 e^{-\lambda\tau}}{\mu_{11}} - \lambda & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\frac{\gamma_2 e^{-\lambda\tau}}{\mu_{12}} - \lambda & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & -\frac{\gamma_3 e^{-\lambda\tau}}{\mu_{13}} - \lambda & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & -\frac{\delta_1 e^{-\lambda\tau}}{\delta_2 e^{-\lambda\tau} - \mu_{14}} - \lambda \end{bmatrix} = 0$$

Solving for eigenvalues we obtain;

$$\begin{aligned} \lambda_1^* &= -\frac{(\omega_2 + \omega_3)e^{-\lambda\tau}}{\mu_8} \\ \lambda_2^* &= -\frac{\omega_4 e^{-\lambda\tau}}{\mu_9} \\ \lambda_3^* &= -\frac{(\omega_5 + \omega_6)e^{-\lambda\tau}}{\mu_{10}} \\ \lambda_4^* &= -\frac{\gamma_1 e^{-\lambda\tau}}{\mu_{11}} \\ \lambda_5^* &= -\frac{\gamma_2 e^{-\lambda\tau}}{\mu_{12}} \\ \lambda_6^* &= -\frac{\gamma_3 e^{-\lambda\tau}}{\mu_{13}} \\ \lambda_7^* &= -\frac{\delta_1 e^{-\lambda\tau}}{\delta_2 e^{-\lambda\tau} - \mu_{14}} \end{aligned}$$

The dominant eigenvalue is

$$\lambda_7^* = -\frac{\delta_1 e^{-\lambda\tau}}{\delta_2 e^{-\lambda\tau} - \mu_{14}}$$

Therefore,  $R_{0(model\ 2.1)} = \lambda_7^* = -\frac{\delta_1 e^{-\lambda\tau}}{\delta_2 e^{-\lambda\tau} - \mu_{14}}$

## 2.4 Disease free equilibrium point and its stability

To clearly understand the dynamics of HIV-1 Coronavirus co infection progresses, we study the stability of Fig. 1. Mathematical epidemiology considers two equilibria points, Disease Free Equilibrium Point (DFE) and Endemic Equilibrium Point (EEP). In this study we analyzed disease free equilibrium point of the system 1 and studied their stabilities. An equilibrium point is attained by setting the right hand side of each equation of system1 to zero, then solving each equation algebraically for the constant solution.

Disease free equilibrium point is a viable region in the solution of system1 in absence of viral infection and co infection. For our model, we see that DFE is set of  $(S^0, V^0, V_n^0, E^0, E_A^0, E_h^0, I_{sh}^0, I_{ah}^0, I_{SA}^0, Q_h^0, H^0, R^0) = (\frac{\phi_2}{\sum \mu}, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)$  for Fig. 1 obtained by simple algebraic computation in the absence of viruses.

### 2.4.1 Stability of disease free equilibrium

The disease free equilibrium is the state of variable of the model in the absence of disease. Its stability can be tested using the eigenvalues of Jacobian matrix obtained at DFE, where at this point reproduction number is less than one. The linearization matrix of system1 is given by:

$$\begin{pmatrix} -\mu_5 - \beta_2 - \beta_3 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ \beta_2 & -\mu_6 - \alpha_2 e^{-\lambda\tau} - \alpha_4 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ \beta_3 & 0 & -\mu_7 - \alpha_3 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & \alpha_2 e^{-\lambda\tau} & \alpha_3 e^{-\lambda\tau} & -\mu_8 - \omega_2 e^{-\lambda\tau} - \omega_3 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & \omega_3 e^{-\lambda\tau} & -\mu_9 - \omega_4 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & \omega_2 e^{-\lambda\tau} & 0 & -\mu_{10} - \omega_5 e^{-\lambda\tau} - \omega_6 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & \omega_5 e^{-\lambda\tau} & -\mu_{11} - \gamma_1 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & \omega_6 e^{-\lambda\tau} & 0 & -\mu_{12} - \gamma_2 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & \omega_4 e^{-\lambda\tau} & 0 & 0 & 0 & -\mu_{13} - \gamma_3 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & \gamma_1 e^{-\lambda\tau} & 0 & 0 & -\delta_1 e^{-\lambda\tau} - \delta_2 e^{-\lambda\tau} - \mu_{14} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & \gamma_2 e^{-\lambda\tau} & \gamma_3 e^{-\lambda\tau} & \delta_1 e^{-\lambda\tau} & \delta_2 e^{-\lambda\tau} & -\mu_{15} & -\Gamma_1 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & \alpha_4 e^{-\lambda\tau} & 0 & 0 & 0 & 0 & 0 & 0 & \delta_1 e^{-\lambda\tau} & \Gamma_1 e^{-\lambda\tau} & -\mu_{16} & -\Gamma_1 e^{-\lambda\tau} & -\mu_{14} & 0 & 0 & 0 & 0 & 0 \end{pmatrix}$$

The system 1(\*) is locally asymptotically stable if all the eigenvalues of linearization matrix of system 1 are negative. Clearly, the eigenvalues are:

$$\begin{aligned} \lambda_1^{**} &= -(\mu_5 + \beta_2 + \beta_3) \\ \lambda_2^{**} &= -(\mu_6 + (\alpha_2 + \alpha_4)e^{-\lambda\tau}) \\ \lambda_3^{**} &= -\mu_7 - \alpha_3 e^{-\lambda\tau} \\ \lambda_4^{**} &= -(\mu_8 + (\omega_2 + \omega_3)e^{-\lambda\tau}) \\ \lambda_5^{**} &= -\mu_9 - \omega_4 e^{-\lambda\tau} \\ \lambda_6^{**} &= -(\mu_{10} + (\omega_5 + \omega_6)e^{-\lambda\tau}) \\ \lambda_7^{**} &= -\mu_{11} - \gamma_1 e^{-\lambda\tau} \\ \lambda_8^{**} &= -\mu_{12} - \gamma_2 e^{-\lambda\tau} \\ \lambda_9^{**} &= -\mu_{13} - \gamma_3 e^{-\lambda\tau} \\ \lambda_{10}^{**} &= -\mu_{14} + ((\delta_1 + \delta_2)e^{-\lambda\tau}) \\ \lambda_{11}^{**} &= -\mu_{15} - \Gamma_1 e^{-\lambda\tau} \\ \lambda_{12}^{**} &= -\mu_{16} \end{aligned}$$

For model 1; it's clear that the dominant eigenvalue is

$$\lambda_{10}^{**} = -\mu_{14} + ((\delta_1 + \delta_2)e^{-\lambda\tau})$$

### Theorem 1.

Disease free equilibrium is stable whenever  $R_0 < 1$  otherwise unstable.

### Proof

$\lambda_{10}^{**}$  should be negative. This can only be negative if;

$$\delta_1 e^{-\lambda\tau} < \delta_2 e^{-\lambda\tau} - \mu_{14}$$

Clearly,

$$\frac{\delta_1 e^{-\lambda\tau}}{\delta_2 e^{-\lambda\tau} - \mu_{14}} < 1$$

Therefore  $R_0 < 1$  is attained for DFE to be stable.

## 2.5 Local and global stability analysis

### Local stability analysis of disease free equilibrium points

Local stability of disease free equilibrium point is the point where if the system is put somewhere nearby the equilibrium point, it will move itself to the equilibrium point in some time.

### Global stability analysis of disease free equilibrium points

Global stability of system 1(\*) was done by constructing Lyapunov functions for disease free equilibrium point.

#### Theorem 2:

If  $R_0 < 1$  then the disease free equilibrium of system 1(\*) is globally asymptotically stable, otherwise unstable if  $R_0 > 1$ .

#### Proof

$$\begin{aligned} v(S, V, V_n, E, E_A, E_h, I_{sh}, I_{ah}, I_{sA}, Q_h, H_h, R) &= (S - S^0)^2 + (V - 0)^2 + \dots + (R - 0)^2 \text{ System 2} \\ &= (S - S^0)^2 + V^2 + \dots + R^2 \end{aligned}$$

From system 2

$$S = \frac{\phi_2}{\mu_5 + \beta_2 + \beta_3} \text{ implying that } S > 0 \text{ hence positive. It follows that}$$

$$V = V_n = E = \dots = R > 0$$

The time derivative of system 2 is

$$\frac{dv}{dt}(S, V, V_n, E, E_A, E_h, I_{sh}, I_{ah}, I_{sA}, Q_h, H_h, R) = 2(S - S^0) \frac{dS}{dt} + 2V \frac{dV}{dt} + \dots + 2R \frac{dR}{dt}$$

At Disease Free Equilibrium Point,  $V = V_n = E = \dots = R = 0$  hence the equation above becomes  $\dot{v} = 2(S - S_0)$ . For global stability  $S < S_0$  so that  $\dot{v} < 0$ . If  $S \leq S_0$  then  $\dot{v} \leq 0$  implying that  $R_0 \leq 1$  hence the Disease Free Equilibrium Point is globally stable.


## 3 Main Results

Analytic solutions can be demonstrated using analytic results with specific numerical examples. The model equation (1) is considered. A numerical simulation of the model is calculated using list of parameters and their estimated values given in the Table 1. The values have been obtained from [23,32,33]. In simulation of the model system (1), the following initial values in each compartment at the onset of infection is assumed to apply;  $(S(0), V(0), V_n(0), E(0), E_A(0), E_h(0), I_{sh}(0), I_{ah}(0), I_{sA}(0), Q_h(0), H(0), R(0)) = (1000, 0, 0.01, 0.01, 500, 30, 0, 0, 0, 0, 0, 0)$  on the interval  $[-\tau, 0]$ .




**Table 1. Table of variable, variable description and value**


Parameters	Parameter description	Value	Source
$S$	susceptible class to both HIV-1 and Coronavirus disease ( $S$ )	2500	Fixed
$V$	Coronavirus disease vaccinated class ( $V$ )	1000	Estimated
$V_n$	Coronavirus disease non-vaccinated class ( $V_n$ )	1500	Estimated
$E$	Exposed class ( $E$ )	100	Estimated
$E_A$	Exposed class with HIV-1 ( $E_h$ )	10	Estimated
$E_h$	Exposed class with AIDs ( $E_A$ )	10	Estimated
$I_{sA}$	symptomatic infected class with AIDs ( $I_{sA}$ )	0	Assumed
$I_{sh}$	symptomatic infected class with HIV-1 ( $I_{sh}$ )	0	Assumed
$I_{ah}$	asymptomatic infected class with HIV-1 ( $I_{ah}$ )	0	Assumed
$Q_h$	Quarantined class with HIV-1 ( $Q_h$ )	15	Estimated
$H$	Hospitalized class ( $H$ )	20	Estimated
$R$	Removed class ( $R$ )	5	Assumed
$\phi_2$	Recruitment rate	2500	16
$\beta_3$	Rate of progression from $S$ to $V$	0.20	Assumed
$\beta_4$	Rate of progression from $S$ to $V_n$	0.002	14
$\alpha_3$	Rate of progression from $V$ to $E$	0.53	Estimated
$\alpha_4$	Rate of progression from $V_n$ to $E$	0.45	Estimated
$\alpha_5$	Rate of progression from $V$ to $R$	0.50	Estimated
$\omega_3$	Rate of progression from $E$ to $E_h$	0.4	Estimated
$\omega_4$	Rate of progression from $E$ to $E_A$	0.05	Estimated
$\omega_5$	Rate of progression from $E_A$ to $I_{sA}$	0.043	Estimated
$\omega_6$	Rate of progression from $E_h$ to $I_{sh}$	0.045	Estimated
$\omega_7$	Rate of progression from $E_h$ to $I_{ah}$	0.3425	Estimated
$\gamma_2$	Rate of progression from $H$ to $R$	0.05	22
$\gamma_3$	Rate of progression from $I_{sh}$ to $Q_h$	0.3	16
$\gamma_4$	Rate of progression from $I_{sA}$ to $H$	0.3	16
$\gamma_5$	Rate of progression from $I_{ah}$ to $H$	0.38	16
$\delta_4$	Rate of progression from $Q_h$ to $R$	0.200	22
$\delta_5$	Rate of progression from $Q_h$ to $H$	0.3	Assumed
$\mu$	Natural death rate	$0.019 < \mu < 0.51$	16




**Fig. 2. population vs time**



**Fig. 3. RO vs death rate**



**Fig. 4. RO vs delta**



**Fig. 5. Ro as a function of Tau**

## 4 Discussion

Numerical results showed that death rate, time lag, vaccination and quarantine affected the growth of the disease as it is seen from reproduction number. Fig. 2 shows cell population with time, clearly the infected individuals curve were at zero initially then it increases steadily, it then reduces after some time when interventions like vaccination, quarantine and treatment were put in place. Further, the curve for susceptible individuals rises

steadily and stabilizes at higher value than the other curves. Figs. 3, 4 and 5 show how reproduction number is affected by death rate, quarantine and time lag respectively. When death rate and number of individuals being taken to quarantine is high then it means that the disease is growing. When time lag is 0.56days then the reproduction number is less than one and it means the disease is dying out.

## 5 Conclusion

Disease Free Equilibrium is attained when  $R_0 < 1$ . This is affected by vaccination, time delay, quarantine and chemotherapy of both HIV-1 and CoVid-19. The study found out that if all other factors are kept constant then DFE is achieved when drug efficacy is above fifty percent. It is also clear that for  $\tau > 0$  DFE is stable and unstable otherwise.

## Competing Interests

Authors have declared that no competing interests exist.

## References

- [1] Batra A, Swaby J, Raval P, Zhu H, Weintraub N, Terris M, et al. (COVID 2022,2). Effect of community and socio-economic factors on cardiovascular. Cancer and cardio-oncology patients with COVID-19. 2022;350-368.
- [2] Betti MNB, Heffernan J, Raad A. Could a NEW COVID-19 Mutant Strain Undermine Vaccination Efforts? A Mathematical modelling approach for estimating the spread of B.1.1.7 Using Ontario, Canada as a Case Study Vaccine; 2021
- [3] Goudiaby MS, GL. Optimal control analysis of a COVID-19 and tuberculosis co-dynamics model. Informatics in Medicine Unlocked. 2022;1-28.
- [4] Kaur ACM, Carpe S, Congrete S, Shahzad H, Reardon J, et al. Post-covid-19. condition and health status. 2022;2:76-86.
- [5] Schlickeiser R, Kröger M. Forecast of omicron wave time evolution. Covid. 2022 Feb 24;2(3):216-29.
- [6] Viona Ojiambo MK. A Human-pathogen SEIR-P Model for COVID-19 Outbreak Under different intervention Scenario in Kenya. Journal of Mathematics. 2020;1-10.
- [7] WR, Mbogo L. Stochastic model for in-host HIV dynamics with therapeutic intervention. Journal of Mathematical Biology. 2013;11.
- [8] Chable-Bessia C, Neyret A, Swain J, Henaut M, Merida P, Gros N, et al. Low selectivity indices of ivermectin and macrocyclic lactones on SARS-COV-2. Replication *In vitro*. COVID. 2022;60-75.
- [9] Cherono Pela KW. Modelling the Effects of Immune Response and Time Delay on HIV-1 *In vivo* Dynamics in the Presence of Chemotherapy. Mathematical Modelling and Applications. 2019;1-7.
- [10] Liu T, Kang LY, Huang J, GUO Z, Xu J, et al. Simultaneous Detection of seven Human Coronaviruses by multiplex PCR and Maldi-Tofms COVID. 2022;5-17.
- [11] Pakwan Riyapan SE. A Mathematical Model of COVID-19 Pandemic A case study of Bangkok, Thailand. Journal of Computational and Mathematical methods of medicine, Hindawi Publishers. 2021;11.
- [12] Purnachandra TS. HIV/AIDS-Pneumonia Codynamics Model Analysis with Vaccination and Treatment. Computation and Mathematical methods in Medicine; 2022.

- [13] Kassahun Getnet Mekonen SF. Mathematical modelling and Analysis of Analysis of TB and COVID-19 coinfection. Journal of applied mathematics Hindawi publishers. 2022;1-20.
- [14] Perelson S. modelling the interaction of immune system with HIV in mathematical and stastical approaches to AIS epidemiology. Journal of Mathematical and Statistics Approaches on AIDs Epidemiology. 1989;350-370.
- [15] Peronace C, Talerico R, Colosimo M, Panduri G, Pintomalli L, RO, et al. B A.I Omicron Variant of SARS-COV-2. First Case Reported in Calabria Region, Italy. COVID. 2022;2:211-215.
- [16] Rahim Ud Din, Kamal Shah IA. Study of transmission dynamics of novel COVID-19 by using mathematical modelling. Journal of Advance in Differrnce Equations, Springer open publishers. 2020;1-13.
- [17] Rahim Ud Din. Kamal Shah IA. Study of transmission dynamics of novel COVID-19 by using mathematical modelling. Journal of Advance in Differrnce Equations, Springer open publishers. 2020;1-13.
- [18] Anwar Zeb EA. SEIQR model for coronavirus disease 2019 containing isolation class. Journal of Biomed Research International Hindawi Publishers. 2020;7.
- [19] Ali Alarjani MT. Application of Mathematical modelling in prediction of COVID-19 transmission dynamics . Journal of computer engineering and computer science, Springer open publishers; 2020.
- [20] Oame ASN. Analysis of COVI-19 and comorbidity co-infection model with optimal control. Optim Control Appl Methods. 2021;1568-1590.
- [21] Organization WH. Modes of Transmission of Virus Causing COVID-19 Implications for IPC Precaution recommendations. WHO Scientific brief. 2020;1-3.
- [22] Otaki JN. Nonsel mutations in the spike protein suggest an increase in the Antigencity and decrease in the Virulence of the Omicron Variant of SARS-Cov-2. 2022;407-418.
- [23] Ahmed Idris DG. An epidemic prediction from analysis of a combined HIV-COVID-19 co-infection model via ABC-fractional operator. Alexandria Engineering Journal. 2021;60:2979-2995.
- [24] Ahmed Idris DG. An epidemic prediction from analysis of a combined HIV-COVID-19 co-infection model via ABC-fractional operator. Alexandria Engineering Journal. 2021;60:2979-2995.
- [25] Ngina Purity M, RW. Mathematical modelling of in vivo dynamics of HIV subject to the influence of the CD8+ T-cells. Journal of Applied Mathematics. 2017;1153-1179.
- [26] Sarbaz HA, Khoshnaw RH. Mathematical Modelling for Coronavirus Disease (COVID-19) in Predicting future behaviors and sensitivity analysis. Journal of Mathematical Modelling of Natural Phenomena; 2020.
- [27] Muthelo Ma. COVID-19 and the Quality of mathematics education, teaching and learning in a first-year course. South African Journal of Higher education. 2022;36(2):189-203.
- [28] Diekmann OJ. On the definition and computation of  $R_0$  in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology. 1990;365-382.
- [29] Organisation WH. Enhancing Response of Omicron. SARS-COV-2 Variant. Technical brief and priority actions for members states. 2022;1-28.

- [30] Bonhoeffer RM. Production of resistant HIV mutants during antiretroviral therapy. *Journal of Applied Mathematics*; 2000.
- [31] Ringa N, ML. HIV and COVID-19 co-infection: A mathematical model and optimal control. *Journal of informatics medicine Elsevier publishers*. 2022;1-17.
- [32] Byul Nim EK. Mathematical Model of COVID-19 Transmission Dynamics in South Korea: The Impact of Travel Restrictions, Social Distancing and Early Detection . *Journal of Maths MDPI Publishers*. 2020;1-18.
- [33] Cho D-H, Choi G. Atorvastatin Reduces Severity of COVID-19. A Nationwide, Total Population-Based, case-control study, *COVID*. 2022;2:398-406.
- [34] Kasia A Pawelek SL. A model of HIV-1 infection with two time delays: Mathematics analysis and comparison with patient data. *Journal of Mathematics Biology*. 2012;98-109.
- [35] Kotola BS, TS. Bifurcation and Optimal control analysis of HIV/AIDS and COVID-19 co-infection model with numerical simulation. *PMCID*. 2023;1-46.

---

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Peer-review history:**

The peer review history for this paper can be accessed here (Please copy paste the total link in your browser address bar)

<https://www.sdiarticle5.com/review-history/116815>